Treat-to-Target in Atopic Dermatitis: An International Consensus on a Set of Core Decision Points for Systemic Therapies
DOI:
https://doi.org/10.2340/00015555-3751Keywords:
atopic dermatitis, eDelphi, consensus, surveys and questionnaires, treat-to-target, systemic treatmentAbstract
Currently no treat-to-target framework to guide systemic treatment in adults with moderate-to-severe atopic dermatitis exists. We sought to reach international consensus through an eDelphi process on a core set of recommendations for such an approach. Recommendations were developed by an international Steering Committee, spanning 3 areas (Guiding Principles, Decision Making, and Outcome Thresholds) and 2 specific time-points; an initial acceptable target at 3 months and an optimal target at 6 months, each based on improvements in patient global assessment plus at least one specific outcome domain. These treat-to-target- orientated recommendations were evaluated by an extended international panel of physicians, nurses and patients. Proposed recommendations were rated using a 9-point Likert scale; for each recommendation, consensus agreement was reached if ≥ 75% of all respondents rated agreement as ≥ 7. Consensus on 16 core recommendations was reached over 2 eDelphi rounds. These provide a framework for shared decision-making on systemic treatment continuation, modification, or discontinuation.
Downloads
References
Wollenberg A, Barbarot S, Bieber T, Christen-Zaech S, Deleuran M, Fink-Wagner A, et al. Consensus-based European guidelines for treatment of atopic eczema (atopic dermatitis) in adults and children: part I. J Eur Acad Dermatol Venereol 2018; 32: 657-682.
DOI: https://doi.org/10.1111/jdv.14891
Wollenberg A, Barbarot S, Bieber T, Christen-Zaech S, Deleuran M, Fink-Wagner A, et al. Consensus-based European guidelines for treatment of atopic eczema (atopic dermatitis) in adults and children: part II. J Eur Acad Dermatol Venereol 2018; 32: 850-878.
DOI: https://doi.org/10.1111/jdv.14888
Smolen JS, Aletaha D, Bijlsma JW, Breedveld FC, Boumpas D, Burmester G, et al. Treating rheumatoid arthritis to target: recommendations of an international task force. Ann Rheum Dis 2010; 69: 631-637.
DOI: https://doi.org/10.1136/ard.2009.123919
Smolen JS, Breedveld FC, Burmester GR, Bykerk V, Dougados M, Emery P, et al. Treating rheumatoid arthritis to target: 2014 update of the recommendations of an international task force. Ann Rheum Dis 2016; 75: 3-15.
DOI: https://doi.org/10.1136/annrheumdis-2015-207524
Ravelli A, Consolaro A, Horneff G, Laxer RM, Lovell DJ, Wulffraat NM, et al. Treating juvenile idiopathic arthritis to target: recommendations of an international task force. Ann Rheum Dis 2018; 77: 819-828.
DOI: https://doi.org/10.1136/annrheumdis-2018-213030
Smolen JS, Schols M, Braun J, Dougados M, FitzGerald O, Gladman DD, et al. Treating axial spondyloarthritis and peripheral spondyloarthritis, especially psoriatic arthritis, to target: 2017 update of recommendations by an international task force. Ann Rheum Dis 2018; 77: 3-17.
DOI: https://doi.org/10.1136/annrheumdis-2017-211734
van Vollenhoven RF, Mosca M, Bertsias G, Isenberg D, Kuhn A, Lerstrom K, et al. Treat-to-target in systemic lupus erythematosus: recommendations from an international task force. Ann Rheum Dis 2014; 73: 958-967.
DOI: https://doi.org/10.1136/annrheumdis-2013-205139
Mrowietz U, Kragballe K, Reich K, Spuls P, Griffiths CE, Nast A, et al. Definition of treatment goals for moderate to severe psoriasis: a European consensus. Arch Dermatol Res 2011; 303: 1-10.
DOI: https://doi.org/10.1007/s00403-010-1080-1
Mrowietz U. Implementing treatment goals for successful long-term management of psoriasis. J Eur Acad Dermatol Venereol 2012; 26: 12-20.
DOI: https://doi.org/10.1111/j.1468-3083.2011.04411.x
Baker C, Mack A, Cooper A, Fischer G, Shumack S, Sidhu S, et al. Treatment goals for moderate to severe psoriasis: an Australian consensus. Australas J Dermatol 2013; 54: 148-154.
DOI: https://doi.org/10.1111/ajd.12014
Gulliver W, Lynde C, Dutz JP, Vender RB, Yeung J, Bourcier M, et al. Think beyond the Skin: 2014 Canadian Expert Opinion Paper on Treating to Target in Plaque Psoriasis. J Cutan Med Surg 2015; 19: 22-27.
DOI: https://doi.org/10.2310/7750.2014.13151
Thyssen JP, Vestergaard C, Deleuran M, de Bruin-Weller MS, Bieber T, Taieb A, et al. European Task Force on Atopic Dermatitis (ETFAD): treatment targets and treatable traits in atopic dermatitis. J Eur Acad Dermatol Venereol 2020; 34: e839-e842.
DOI: https://doi.org/10.1111/jdv.16716
Leshem YA, Chalmers JR, Apfelbacher C, Furue M, Gerbens LAA, Prinsen CAC, et al. Measuring atopic eczema symptoms in clinical practice: the first consensus statement from the Harmonising Outcome Measures for Eczema in clinical practice initiative. J Am Acad Dermatol 2020; 82: 1181-1186.
DOI: https://doi.org/10.1016/j.jaad.2019.12.055
Vermeulen FM, Gerbens LAA, Bosma AL, Apfelbacher CJ, Irvine AD, Arents BWM, et al. TREatment of ATopic eczema (TREAT) Registry Taskforce: consensus on how and when to measure the core dataset for atopic eczema treatment research registries. Br J Dermatol 2019; 181: 492-504.
DOI: https://doi.org/10.1111/bjd.17715
Gooderham MJ, Bissonnette R, Grewal P, Lansang P, Papp KA, Hong CH. Approach to the assessment and management of adult patients with atopic dermatitis: a Consensus document. Section II: Tools for Assessing the Severity of Atopic Dermatitis. J Cutan Med Surg 2018; 22: 10S-16S.
DOI: https://doi.org/10.1177/1203475418803628
Gerbens LA, Boyce AE, Wall D, Barbarot S, de Booij RJ, Deleuran M, et al. TREatment of ATopic eczema (TREAT) Registry Taskforce: protocol for an international Delphi exercise to identify a core set of domains and domain items for national atopic eczema registries. Trials 2017; 18: 87.
DOI: https://doi.org/10.1186/s13063-016-1765-7
Gerbens LAA, Apfelbacher CJ, Irvine AD, Barbarot S, de Booij RJ, Boyce AE, et al. TREatment of ATopic eczema (TREAT) Registry Taskforce: an international Delphi exercise to identify a core set of domains and domain items for national atopic eczema photo- and systemic therapy registries. Br J Dermatol 2019; 180: 790-801.
DOI: https://doi.org/10.1111/bjd.16714
Chalmers JR, Thomas KS, Apfelbacher C, Williams HC, Prinsen CA, Spuls PI, et al. Report from the fifth international consensus meeting to harmonize core outcome measures for atopic eczema/dermatitis clinical trials (HOME initiative). Br J Dermatol 2018; 178: e332-e341.
Armstrong AW, Siegel MP, Bagel J, Boh EE, Buell M, Cooper KD, et al. From the Medical Board of the National Psoriasis Foundation: treatment targets for plaque psoriasis. J Am Acad Dermatol 2017; 76: 290-298.
DOI: https://doi.org/10.1016/j.jaad.2016.10.017
Grine L, de la Brassinne M, Ghislain PD, Hillary T, Lambert J, Segaert S, et al. A Belgian consensus on the definition of a treat-to-target outcome set in psoriasis management. J Eur Acad Dermatol Venereol 2020; 34: 676-684.
DOI: https://doi.org/10.1111/jdv.16104
Simpson E, Eckert L, Gadkari A, Mallya UG, Yang M, Nelson L, et al. Validation of the Atopic Dermatitis Control Tool (ADCT(c)) using a longitudinal survey of biologic-treated patients with atopic dermatitis. BMC Dermatol 2019; 19: 15.
DOI: https://doi.org/10.1186/s12895-019-0095-3
Pariser DM, Simpson EL, Gadkari A, Bieber T, Margolis DJ, Brown M, et al. Evaluating patient-perceived control of atopic dermatitis: design, validation, and scoring of the Atopic Dermatitis Control Tool (ADCT). Curr Med Res Opin 2020; 36: 367-376.
DOI: https://doi.org/10.1080/03007995.2019.1699516
Howells L, Chalmers JR, Gran S, Ahmed A, Apfelbacher C, Burton T, et al. Development and initial testing of a new instrument to measure the experience of eczema control in adults and children: Recap of atopic eczema (RECAP). Br J Dermatol 2020; 183: 524-536.
Additional Files
Published
How to Cite
License
Copyright (c) 2021 Marjolein S. De Bruin-Weller, Tilo Biedermann, Robert Bissonnette, Mette Deleuran, Peter Foley, Giampiero Girolomoni, Jana Hercogová, Chih-Ho Hong, Norito Katoh, Andrew E. Pink, Marie-Aleth Richard, Stephen Shumack, Juan F. Silvestre, Stephan Weidinger
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
All digitalized ActaDV contents is available freely online. The Society for Publication of Acta Dermato-Venereologica owns the copyright for all material published until volume 88 (2008) and as from volume 89 (2009) the journal has been published fully Open Access, meaning the authors retain copyright to their work.
Unless otherwise specified, all Open Access articles are published under CC-BY-NC licences, allowing third parties to copy and redistribute the material in any medium or format and to remix, transform, and build upon the material for non-commercial purposes, provided proper attribution to the original work.